Cargando…
Comment on: ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405217/ https://www.ncbi.nlm.nih.gov/pubmed/22743830 http://dx.doi.org/10.1038/bjc.2012.280 |
| _version_ | 1782239099189460992 |
|---|---|
| author | Bielack, S S |
| author_facet | Bielack, S S |
| author_sort | Bielack, S S |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3405217 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2012 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-34052172013-07-24 Comment on: ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’ Bielack, S S Br J Cancer Letter to the Editor Nature Publishing Group 2012-07-24 2012-06-28 /pmc/articles/PMC3405217/ /pubmed/22743830 http://dx.doi.org/10.1038/bjc.2012.280 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Bielack, S S Comment on: ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’ |
| title | Comment on: ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’ |
| title_full | Comment on: ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’ |
| title_fullStr | Comment on: ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’ |
| title_full_unstemmed | Comment on: ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’ |
| title_short | Comment on: ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’ |
| title_sort | comment on: ‘developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’ |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405217/ https://www.ncbi.nlm.nih.gov/pubmed/22743830 http://dx.doi.org/10.1038/bjc.2012.280 |
| work_keys_str_mv | AT bielackss commentondevelopingandpayingformedicinesfororphanindicationsinoncologyutilitarianregulationvsequitablecare |